Download PDF
Am J Perinatol 2018; 35(09): 898-903
DOI: 10.1055/s-0038-1627096
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Heparin-Induced Thrombocytopenia during Obstetric Hospital Admissions

Deepika Sagaram
1   Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York
,
Zainab Siddiq
1   Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York
,
Andrew B. Eisenberger
2   Division of Hematology/Oncology, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York
,
Cande V. Ananth
1   Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York
3   Department of Epidemiology, Joseph L. Mailman School of Public Health, Columbia University, New York, New York
,
Jason D. Wright
1   Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York
,
Mary E. D'Alton
1   Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York
,
Alexander M. Friedman
1   Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, New York, New York
› Author Affiliations
Further Information

Publication History

09 October 2017

29 December 2017

Publication Date:
08 February 2018 (online)

    Permissions and Reprints

Abstract

Introduction The rate of heparin-induced thrombocytopenia (HIT) on a population basis is unknown. The objective of this study was to characterize the risk for HIT during antepartum, delivery, and postpartum hospitalizations in the United States.

Materials and Methods A large administrative database was used to determine the risk of HIT in hospitalized obstetric patients who received unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Patients were presumed to have HIT if they were exposed to UFH or LMWH, received a diagnosis of HIT, and were administered a medication for the treatment of HIT including bivalirudin, argatroban, fondaparinux, or lepirudin. We queried severe complications of HIT including arterial thrombosis, limb amputation, heart failure, and death.

Results We identified 66,468 antepartum hospitalizations, 66,741 delivery hospitalizations, and 16,325 postpartum readmissions where women received pharmacologic prophylaxis. Of these, 10 antepartum admissions, 1 delivery admission, and 14 postpartum readmissions involved a diagnosis of HIT with treatment of bivalirudin, argatroban, fondaparinux, or lepirudin. There were no deaths and no diagnoses of arterial thrombosis, limb amputation, heart failure, and death.

Conclusion Risk for HIT among hospitalized obstetric patients is low. In this cohort, no cases of death or severe complications were noted in relation to the diagnosis.

Keywords

heparin-induced thrombocytopenia - obstetric thromboembolism - thromboembolism prophylaxis

Note

Dr. Friedman is supported by a career development award (K08HD082287) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health.


 

  • References

  • 1 Linkins LA, Dans AL, Moores LK. , et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl) e495S-e530S
    CrossrefPubMedGoogle Scholar
  • 2 Salter BS, Weiner MM, Trinh MA. , et al. Heparin-induced thrombocytopenia: a comprehensive clinical review. J Am Coll Cardiol 2016; 67 (21) 2519-2532
    CrossrefPubMedGoogle Scholar
  • 3 Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1 (07) 1471-1478
    CrossrefPubMedGoogle Scholar
  • 4 Warkentin TE, Levine MN, Hirsh J. , et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332 (20) 1330-1335
    CrossrefPubMedGoogle Scholar
  • 5 Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest 2007; 131 (06) 1644-1649
    CrossrefPubMedGoogle Scholar
  • 6 Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108 (09) 2937-2941
    CrossrefPubMedGoogle Scholar
  • 7 Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 2009; 122 (10) 919-930
    CrossrefPubMedGoogle Scholar
  • 8 Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106 (02) 401-407
    CrossrefPubMedGoogle Scholar
  • 9 Quiñones JN, James DN, Stamilio DM, Cleary KL, Macones GA. Thromboprophylaxis after cesarean delivery: a decision analysis. Obstet Gynecol 2005; 106 (04) 733-740
    CrossrefPubMedGoogle Scholar
  • 10 Fausett MB, Vogtlander M, Lee RM. , et al. Heparin-induced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 2001; 185 (01) 148-152
    CrossrefPubMedGoogle Scholar
  • 11 DʼAlton ME, Friedman AM, Smiley RM. , et al. National partnership for maternal safety: consensus bundle on venous thromboembolism. Obstet Gynecol 2016; 128 (04) 688-698
    CrossrefPubMedGoogle Scholar
  • 12 The Royal College of Obstetricians and Gynaecologists. Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk. Green-Top Guideline No. 37a; 2015
    PubMedGoogle Scholar
  • 13 Cantwell R, Clutton-Brock T, Cooper G. , et al. Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer: 2006-2008. The Eighth Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. BJOG 2011; 118 (Suppl. 01) 1-203
    PubMedGoogle Scholar
  • 14 Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol 2015; 125 (01) 5-12
    CrossrefPubMedGoogle Scholar
  • 15 Callaghan WM, Creanga AA, Kuklina EV. Severe maternal morbidity among delivery and postpartum hospitalizations in the United States. Obstet Gynecol 2012; 120 (05) 1029-1036
    CrossrefPubMedGoogle Scholar
  • 16 Kuklina EV, Whiteman MK, Hillis SD. , et al. An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J 2008; 12 (04) 469-477
    CrossrefPubMedGoogle Scholar
  • 17 Stulberg JJ, Delaney CP, Neuhauser DV, Aron DC, Fu P, Koroukian SM. Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA 2010; 303 (24) 2479-2485
    CrossrefPubMedGoogle Scholar
  • 18 Fang MC, Maselli J, Lurie JD, Lindenauer PK, Pekow PS, Auerbach AD. Use and outcomes of venous thromboembolism prophylaxis after spinal fusion surgery. J Thromb Haemost 2011; 9 (07) 1318-1325
    CrossrefPubMedGoogle Scholar
  • 19 Ritch JM, Kim JH, Lewin SN. , et al. Venous thromboembolism and use of prophylaxis among women undergoing laparoscopic hysterectomy. Obstet Gynecol 2011; 117 (06) 1367-1374
    CrossrefPubMedGoogle Scholar
  • 20 Wright JD, Lewin SN, Shah M. , et al. Quality of venous thromboembolism prophylaxis in patients undergoing oncologic surgery. Ann Surg 2011; 253 (06) 1140-1146
    CrossrefPubMedGoogle Scholar
  • 21 Zacharia BE, Youngerman BE, Bruce SS. , et al. Quality of postoperative venous thromboembolism prophylaxis in neuro-oncologic surgery. Neurosurgery 2017; 80 (01) 73-81
    PubMedGoogle Scholar
  • 22 Prabhakaran S, Herbers P, Khoury J. , et al. Is prophylactic anticoagulation for deep venous thrombosis common practice after intracerebral hemorrhage?. Stroke 2015; 46 (02) 369-375
    CrossrefPubMedGoogle Scholar
  • 23 Kulik A, Rassen JA, Myers J. , et al. Comparative effectiveness of preventative therapy for venous thromboembolism after coronary artery bypass graft surgery. Circ Cardiovasc Interv 2012; 5 (04) 590-596
    CrossrefPubMedGoogle Scholar
  • 24 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106 (08) 2710-2715
    CrossrefPubMedGoogle Scholar
  • 25 Chaudhary RK, Nepal C, Khanal N, Pathak R, Giri S, Bhatt VR. Management and outcome of heparin-induced thrombocytopenia in pregnancy: a systematic review. Cardiovasc Hematol Agents Med Chem 2015; 13 (02) 92-97
    CrossrefPubMedGoogle Scholar
  • 26 Sanson BJ, Lensing AW, Prins MH. , et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81 (05) 668-672
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Lepercq J, Conard J, Borel-Derlon A. , et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. BJOG 2001; 108 (11) 1134-1140
    PubMedGoogle Scholar
  • 28 Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG 2000; 107 (09) 1116-1121
    CrossrefPubMedGoogle Scholar
  • 29 Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis. Blood 2012; 120 (20) 4160-4167
    CrossrefPubMedGoogle Scholar
  • 30 White RH, Brickner LA, Scannell KA. ICD-9-CM codes poorly identified venous thromboembolism during pregnancy. J Clin Epidemiol 2004; 57 (09) 985-988
    CrossrefPubMedGoogle Scholar
  • 31 White RH, Garcia M, Sadeghi B. , et al. Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 2010; 126 (01) 61-67
    CrossrefPubMedGoogle Scholar